PharmacogenomicsPub Date : 2024-02-01Epub Date: 2024-03-05DOI: 10.2217/pgs-2023-0193
Rebekah Ryanne Wu, Richelle Benevent, Nina R Sperber, Jill S Bates, Daniel Villa, Dilhan Weeraratne, Timothy A Burrell, Deepak Voora
{"title":"Workforce readiness for pharmacogenomics and key elements for sustainment within the Veterans Health Administration.","authors":"Rebekah Ryanne Wu, Richelle Benevent, Nina R Sperber, Jill S Bates, Daniel Villa, Dilhan Weeraratne, Timothy A Burrell, Deepak Voora","doi":"10.2217/pgs-2023-0193","DOIUrl":"10.2217/pgs-2023-0193","url":null,"abstract":"<p><p><b>Aim:</b> Understanding barriers and facilitators to pharmacogenomics (PGx) implementation and how to structure a clinical program with the Veterans Health Administration (VA). <b>Materials & methods:</b> Healthcare provider (HCP) survey at 20 VA facilities assessing PGx knowledge/acceptance and qualitative interviews to understand how best to design and sustain a national program. <b>Results:</b> 186 (12% response rate) surveyed believed PGx informs drug efficacy (74.7%) and adverse events (71.0%). Low confidence in knowledge (43.0%) and ability to implement (35.4-43.5%). 23 (60.5% response rate) interviewees supported a nationally program to oversee VA education, consultation and IT resources. Prescribing HCPs should be directing local activities. <b>Conclusion:</b> HCPs recognize PGx value but are not prepared to implement. Healthcare systems should build system-wide programs for implementation education and support.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"133-145"},"PeriodicalIF":2.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10964838/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140028675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PharmacogenomicsPub Date : 2024-02-01Epub Date: 2024-03-20DOI: 10.2217/pgs-2023-0229
Ana I Lopez-Medina, Alessandra M Campos-Staffico, Choudhary Anwar A Chahal, Isabella Volkers, Juliet P Jacoby, Omer Berenfeld, Jasmine A Luzum
{"title":"Genetic risk factors for drug-induced long QT syndrome: findings from a large real-world case-control study.","authors":"Ana I Lopez-Medina, Alessandra M Campos-Staffico, Choudhary Anwar A Chahal, Isabella Volkers, Juliet P Jacoby, Omer Berenfeld, Jasmine A Luzum","doi":"10.2217/pgs-2023-0229","DOIUrl":"10.2217/pgs-2023-0229","url":null,"abstract":"<p><p><b>Aim:</b> Drug-induced long QT syndrome (diLQTS), an adverse effect of many drugs, can lead to sudden cardiac death. Candidate genetic variants in cardiac ion channels have been associated with diLQTS, but several limitations of previous studies hamper clinical utility. <b>Materials & methods:</b> Thus, the purpose of this study was to assess the associations of <i>KCNE1</i>-D85N, <i>KCNE2</i>-I57T and <i>SCN5A</i>-G615E with diLQTS in a large observational case-control study (6,083 self-reported white patients treated with 27 different high-risk QT-prolonging medications; 12.0% with diLQTS). <b>Results:</b> <i>KCNE1</i>-D85N significantly associated with diLQTS (adjusted odds ratio: 2.24 [95% CI: 1.35-3.58]; p = 0.001). Given low minor allele frequencies, the study had insufficient power to analyze <i>KCNE2</i>-I57T and <i>SCN5A</i>-G615E. <b>Conclusion:</b> <i>KCNE1</i>-D85N is a risk factor for diLQTS that should be considered in future clinical practice guidelines.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":"25 3","pages":"117-131"},"PeriodicalIF":2.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10964839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140175960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The genomic landscape of <i>CYP2D6</i> variation in the Indian population.","authors":"Ambily Sivadas, Surabhi Rathore, S Sahana, Bani Jolly, Rahul C Bhoyar, Abhinav Jain, Disha Sharma, Mohamed Imran, Vigneshwar Senthilvel, Mohit Kumar Divakar, Anushree Mishra, Sridhar Sivasubbu, Vinod Scaria","doi":"10.2217/pgs-2023-0233","DOIUrl":"10.2217/pgs-2023-0233","url":null,"abstract":"<p><p><b>Aim:</b> The <i>CYP2D6</i> gene is highly polymorphic, causing large interindividual variability in the metabolism of several clinically important drugs. <b>Materials & methods:</b> The authors investigated the diversity and distribution of <i>CYP2D6</i> alleles in Indians using whole genome sequences (N = 1518). Functional consequences were assessed using pathogenicity scores and molecular dynamics simulations. <b>Results:</b> The analysis revealed population-specific <i>CYP2D6</i> alleles (<i>*86</i>, <i>*7</i>, <i>*111</i>, <i>*112</i>, <i>*113</i>, <i>*99</i>) and remarkable differences in variant and phenotype frequencies with global populations. The authors observed that one in three Indians could benefit from a dose alteration for psychiatric drugs with accurate <i>CYP2D6</i> phenotyping. Molecular dynamics simulations revealed large conformational fluctuations, confirming the predicted reduced function of <i>*86</i> and <i>*113</i> alleles. <b>Conclusion:</b> The findings emphasize the utility of comprehensive <i>CYP2D6</i> profiling for aiding precision public health.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"147-160"},"PeriodicalIF":2.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139997083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PharmacogenomicsPub Date : 2024-02-01Epub Date: 2024-03-05DOI: 10.2217/pgs-2023-0238
Francesco Pepe, Konstantinos Venetis, Giulia Cursano, Chiara Frascarelli, Pasquale Pisapia, Davide Vacirca, Claudia Scimone, Alessandra Rappa, Gianluca Russo, Eltjona Mane, Fabio Pagni, Isabella Castellano, Giancarlo Troncone, Carmine De Angelis, Giuseppe Curigliano, Elena Guerini-Rocco, Umberto Malapelle, Nicola Fusco
{"title":"<i>PIK3CA</i> testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories.","authors":"Francesco Pepe, Konstantinos Venetis, Giulia Cursano, Chiara Frascarelli, Pasquale Pisapia, Davide Vacirca, Claudia Scimone, Alessandra Rappa, Gianluca Russo, Eltjona Mane, Fabio Pagni, Isabella Castellano, Giancarlo Troncone, Carmine De Angelis, Giuseppe Curigliano, Elena Guerini-Rocco, Umberto Malapelle, Nicola Fusco","doi":"10.2217/pgs-2023-0238","DOIUrl":"10.2217/pgs-2023-0238","url":null,"abstract":"<p><p><b>Introduction:</b> <i>PIK3CA</i> gene mutations occur in approximately 40% of hormone receptor-positive/HER2-negative (HR<sup>+</sup>/HER2<sup>-</sup>) metastatic breast cancers (MBCs), electing them to targeted therapy. Testing <i>PIK3CA</i> status is complex due to selection of biological specimen and testing method. <b>Materials & methods:</b> This work investigates real-life experience on <i>PIK3CA</i> testing in HR<sup>+</sup>/HER2<sup>-</sup> MBC. Clinical, technical and molecular data on <i>PIK3CA</i> testing were collected from two referral laboratories. Additionally, the results of a nationwide <i>PIK3CA</i> survey involving 116 institutions were assessed. <b>Results:</b> Overall, n = 35 MBCs were <i>PIK3CA</i>-mutated, with mutations mostly occurring in exons 9 (n = 19; 51.4%) and 20 (n = 15; 40.5%). The nationwide survey revealed significant variability across laboratories in terms of sampling methodology, technical assessment and clinical report signing healthcare figures for <i>PIK3CA</i> molecular testing in diagnostic routine practice. <b>Conclusion:</b> This study provides insights into the real-world routine of <i>PIK3CA</i> testing in HR<sup>+</sup>/HER2<sup>-</sup> MBC and highlights the need for standardization and networking in predictive pathology.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"161-169"},"PeriodicalIF":2.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140028674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PharmacogenomicsPub Date : 2024-01-01Epub Date: 2023-12-19DOI: 10.2217/pgs-2023-0228
Sarah Jones
{"title":"Overview of the year 2023 at <i>Pharmacogenomics</i>.","authors":"Sarah Jones","doi":"10.2217/pgs-2023-0228","DOIUrl":"10.2217/pgs-2023-0228","url":null,"abstract":"","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"1-3"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138807394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PharmacogenomicsPub Date : 2024-01-01Epub Date: 2024-10-25DOI: 10.1080/14622416.2024.2409060
Alenka Šmid, Dunja Urbančič, Jaka Vrevc Žlajpah, Natalia Stollarova, Tomaž Prelog, Marko Kavčič, Janez Jazbec, Irena Mlinarič-Raščan, Nataša Karas Kuželički
{"title":"Genetic profiling of <i>NUDT15</i> in the Slovenian population.","authors":"Alenka Šmid, Dunja Urbančič, Jaka Vrevc Žlajpah, Natalia Stollarova, Tomaž Prelog, Marko Kavčič, Janez Jazbec, Irena Mlinarič-Raščan, Nataša Karas Kuželički","doi":"10.1080/14622416.2024.2409060","DOIUrl":"10.1080/14622416.2024.2409060","url":null,"abstract":"<p><p>Determining variant <i>TPMT</i> alleles to predict patient response to thiopurine therapy represents one of the first successful implementations of pharmacogenomics in clinical practice. However, despite the <i>TPMT</i>-adjusted thiopurine dosing, some <i>TPMT</i> wild-type patients still exhibit toxicity at standard doses. Over the past decade, the pharmacogene <i>NUDT15</i> has emerged as a significant co-modulator of thiopurine therapy. Initially, <i>NUDT15</i> was considered important predominantly in Asian populations, but recent studies have highlighted its relevance in European populations as well.To evaluate the pharmacogenetic significance of <i>NUDT15</i> in the Slovenian population, we sequenced extended regions of exon 1 and exon 3 in 109 healthy individuals and 37 patients with acute lymphoblastic leukemia.We identified eight variants, including one with established clinical significance (allele *3) and one extremely rare variant (Chr13 at 48045861; GRCh38, NC_000013.11). The frequencies of most previously described variants in both the general population and in the ALL cohort were consistent with those reported in other European populations, except for rs45465203, which was less frequent in the Slovenian population. None of the variants, except for <i>NUDT15*3</i>, were associated with cumulative thiopurine doses in ALL patients. However, these variants warrant further investigation in larger ALL cohorts.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"515-525"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PharmacogenomicsPub Date : 2024-01-01Epub Date: 2024-11-15DOI: 10.1080/14622416.2024.2428587
Susanne B Haga
{"title":"Artificial intelligence, medications, pharmacogenomics, and ethics.","authors":"Susanne B Haga","doi":"10.1080/14622416.2024.2428587","DOIUrl":"10.1080/14622416.2024.2428587","url":null,"abstract":"<p><p>Artificial Intelligence (AI) and Machine Learning (ML) are revolutionizing various scientific and clinical disciplines including pharmacogenomics (PGx) by enabling the analysis of complex datasets and the development of predictive models. The integration of AI and ML with PGx has the potential to provide more precise, data-driven insights into new drug targets, drug efficacy, drug selection, and risk of adverse events. While significant effort to develop and validate these tools remain, ongoing advancements in AI technologies, coupled with improvements in data quality and depth is anticipated to drive the transition of these tools into clinical practice and delivery of individualized treatments and improved patient outcomes. The successful development and integration of AI-assisted PGx tools will require careful consideration of ethical, legal, and social issues (ELSI) in research and clinical practice. This paper explores the intersection of PGx with AI, highlighting current research and potential clinical applications, and ELSI including privacy, oversight, patient and provider knowledge and acceptance, and the impact on patient-provider relationship and new roles.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"611-622"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PharmacogenomicsPub Date : 2024-01-01Epub Date: 2024-01-17DOI: 10.2217/pgs-2023-0230
Pedro Dorado, Eva M Peñas-Lledó
{"title":"Pharmacogenetic and pharmacogenomic treatment of rheumatoid arthritis: a review of Pharmacogenomics Knowledge Base scientific evidence.","authors":"Pedro Dorado, Eva M Peñas-Lledó","doi":"10.2217/pgs-2023-0230","DOIUrl":"10.2217/pgs-2023-0230","url":null,"abstract":"<p><p>Tweetable abstract Update on the genetic variants with the highest level of Pharmacogenomics Knowledge Base evidence for their association with toxicity and efficacy in response to the most commonly used disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"55-58"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139478778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PharmacogenomicsPub Date : 2024-01-01Epub Date: 2024-08-07DOI: 10.1080/14622416.2024.2370761
Sadiq Aliyu Hussaini, Bala Waziri, Caroline Dickens, Raquel Duarte
{"title":"Pharmacogenetics of Calcineurin inhibitors in kidney transplant recipients: the African gap. A narrative review.","authors":"Sadiq Aliyu Hussaini, Bala Waziri, Caroline Dickens, Raquel Duarte","doi":"10.1080/14622416.2024.2370761","DOIUrl":"10.1080/14622416.2024.2370761","url":null,"abstract":"<p><p>Calcineurin inhibitors (CNIs) are the mainstay of immunosuppression in kidney transplantation. Interpatient variability in the disposition of calcineurin inhibitors is a well-researched phenomenon and has a well-established genetic contribution. There is great diversity in the makeup of African genomes, but very little is known about the pharmacogenetics of CNIs and transplant outcomes. This review focuses on genetic variants of calcineurin inhibitors' metabolizing enzymes (CYP3A4, CYP3A5), related molecules (POR, PPARA) and membrane transporters involved in the metabolism of calcineurin inhibitors. Given the genetic diversity across the African continent, it is imperative to generate pharmacogenetic data, especially in the era of personalized medicine and emphasizes the need for studies specific to African populations. The study of allelic variants in populations where they have greater frequencies will help answer questions regarding their impact. We aim to fill the knowledge gaps by reviewing existing research and highlighting areas where African research can contribute.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"329-341"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11404701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141898013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Impact of genetic variants on fentanyl metabolism in major breast surgery patients: a candidate gene association study.","authors":"Shathish Kumar, Kesavan Ramasamy, Harivenkatesh Natarajan, Shravan Venkatraman, Vishnu Eriyat, Pankaj Kundra","doi":"10.1080/14622416.2024.2429365","DOIUrl":"10.1080/14622416.2024.2429365","url":null,"abstract":"<p><strong>Aim: </strong>The study aimed to examine the association of two selected candidate SNPs rs2242480 (CYP3A4) and rs1045642 (ABCB1) with metabolic ratio of plasma norfentanyl to fentanyl concentrations in patients undergoing major breast surgeries.</p><p><strong>Methods: </strong>The retrospective cross-sectional study was done in 257 female patients. DNA extraction, genotyping of selected SNPs, and drug levels measurement were employed.</p><p><strong>Results: </strong>A total of 257 female patients were recruited with no loss to follow up. There was no significant association between the two mentioned SNPs and the metabolic ratio (<i>p</i> value > 0.05). As an exploratory analysis, there was a moderately significant negative correlation between metabolic ratio and pupillary constriction to fentanyl (<i>r</i> = -0.27; <i>p</i> < 0.001). There was also a weak but significant positive correlation between metabolic ratio and time for first analgesia in the postoperative period (<i>r</i> = 0.17; <i>p</i> = 0.01).</p><p><strong>Conclusion: </strong>There was no significant association with the selected candidate SNPs in <i>CYP3A4</i> and <i>ABCB1 genes</i> and metabolic ratio of norfentanyl to fentanyl in South Indian patients undergoing major breast surgery.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"595-603"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}